| Prevalence | 0.02-0.05% of the global population (200-500 per million) |
| Excessive daytime sleepiness | Overwhelming urge to sleep during the day |
| Cataplexy | Sudden loss of muscle tone triggered by strong emotions |
| Sleep paralysis | Temporary inability to move during sleep transitions |
| Hypnagogic/hypnopompic hallucinations | Vivid dream-like experiences at sleep onset or offset |
| Disrupted nighttime sleep | Fragmented sleep architecture |
| Incidence | 0.5-1 per 100,000 person-years |
| Age of onset | Bimodal distribution — peaks at 15 years and 35 years |
| Gender | Slight male predominance (1.3-1.5:1) |
| HLA-DQB1*06:02 | Present in >95% of type 1 narcolepsy cases |
| Family history | 10-40x increased risk in first-degree relatives |
| Environment | Infections (particularly Streptococcus pyogenes), vaccines, stress |
| Databases | OMIMOrphanetClinicalTrialsPubMed |